ASX Stocks That Could Be Undervalued In April 2025
In the wake of recent market volatility driven by global tariff tensions, Australian shares are poised for a significant downturn, with ASX 200 futures indicating a sharp decline. Amidst this challenging environment, identifying undervalued stocks requires careful analysis of fundamentals and resilience to external economic pressures.
Name
Current Price
Fair Value (Est)
Discount (Est)
Acrow (ASX:ACF)
A$1.035
A$2.04
49.3%
Nick Scali (ASX:NCK)
A$15.01
A$28.70
47.7%
GenusPlus Group (ASX:GNP)
A$2.65
A$5.20
49%
Environmental Group (ASX:EGL)
A$0.24
A$0.47
49.4%
PolyNovo (ASX:PNV)
A$1.05
A$2.06
49.1%
Amaero International (ASX:3DA)
A$0.26
A$0.46
43.6%
James Hardie Industries (ASX:JHX)
A$34.84
A$60.84
42.7%
SciDev (ASX:SDV)
A$0.43
A$0.84
48.5%
Integral Diagnostics (ASX:IDX)
A$2.28
A$4.07
44%
Pantoro (ASX:PNR)
A$2.55
A$4.92
48.2%
Click here to see the full list of 41 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.
Here's a peek at a few of the choices from the screener.
Overview: Capricorn Metals Ltd is involved in the evaluation, exploration, development, and production of gold properties in Australia with a market cap of A$3.50 billion.
Operations: The company's revenue primarily comes from its Karlawinda gold operations, generating A$379.47 million.
Estimated Discount To Fair Value: 26.6%
Capricorn Metals is trading at A$8.47, below its estimated fair value of A$11.54, suggesting it may be undervalued based on cash flows. Recent earnings results show sales increased to A$201.37 million for the half year ending December 2024, although net income decreased to A$43.11 million compared to the previous year. Despite this, revenue and earnings are forecasted to grow significantly faster than the market, with a high return on equity expected in three years.
Our expertly prepared growth report on Capricorn Metals implies its future financial outlook may be stronger than recent results.
Click here and access our complete balance sheet health report to understand the dynamics of Capricorn Metals.
Overview: Nanosonics Limited is a global infection prevention company with a market capitalization of A$1.42 billion.
Operations: The company generates revenue primarily from its Healthcare Equipment segment, which accounts for A$183.97 million.
Estimated Discount To Fair Value: 34.3%
Nanosonics is trading at A$4.64, below its estimated fair value of A$7.06, indicating potential undervaluation based on cash flows. Recent earnings show sales increased to A$93.6 million for H1 2025, with net income rising to A$9.76 million year-over-year. Revenue and earnings are forecasted to grow significantly faster than the market, though return on equity remains low in future projections. The company has also revised its revenue growth guidance upwards for early 2025.
According our earnings growth report, there's an indication that Nanosonics might be ready to expand.
Click to explore a detailed breakdown of our findings in Nanosonics' balance sheet health report.
Overview: Sigma Healthcare Limited is a pharmaceutical wholesaler, distributor, and pharmacy franchisor operating in Australia and internationally with a market cap of A$33.36 billion.
Operations: The company generates revenue primarily through its Wholesale and Retail Services Segment, which accounts for A$3.29 billion.
Estimated Discount To Fair Value: 15.1%
Sigma Healthcare, trading at A$2.89, is below its estimated fair value of A$3.4, suggesting it may be undervalued based on cash flows. Revenue is projected to grow 39.2% annually, outpacing the Australian market's 5.8%. Earnings are expected to increase by 15.3% per year but remain below significant growth levels and face substantial insider selling recently. Sigma's inclusion in major indices like S&P/ASX 100 highlights its market relevance despite these challenges.
Our growth report here indicates Sigma Healthcare may be poised for an improving outlook.
Navigate through the intricacies of Sigma Healthcare with our comprehensive financial health report here.
Unlock more gems! Our Undervalued ASX Stocks Based On Cash Flows screener has unearthed 38 more companies for you to explore.Click here to unveil our expertly curated list of 41 Undervalued ASX Stocks Based On Cash Flows.
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:CMM ASX:NAN and ASX:SIG.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Here are the most and least expensive U.S. cities for raising a child
Parents know that raising a child is expensive, but exactly how much does the annual cost of food, childcare and other expenses add up to? A new analysis from SmartAsset crunched data from 48 of the largest U.S. cities to find out how much money parents across the country are spending annually on raising their children. The answer: families on average spend more than $26,000 a year on child-rearing costs, the personal finance site found. The study also found that such expenses can fluctuate sharply year to year. In St. Louis, Missouri, for example, the cost of raising a child has shot up over 20% over the last year. Here are the cities where it's the most and least expensive to raise a child. Where is it most expensive to raise a child? 1. Boston—Cambridge—Newton, MA Total annual cost of raising a child in 2025: $39,221Total annual cost of raising a child in 2024: $37,758Percent change: 3.87% 2. San Francisco—Oakland—Fremont, CA Total annual cost of raising a child in 2025: $38,981Total annual cost of raising a child in 2024: $35,642Percent change: 9.37% 3. San Jose—Sunnyvale—Santa Clara, CA Total annual cost of raising a child in 2025: $37,867Total annual cost of raising a child in 2024: $34,415Percent change: 10.03% 4. Seattle—Tacoma—Bellevue, WA Total annual cost of raising a child in 2025: $34,448Total annual cost of raising a child in 2024: $30,781Percent change: 11.91% 5. Hartford-West Hartford-East Hartford, CT Total annual cost of raising a child in 2025: $33,149 Total annual cost of raising a child in 2024: $32,135Percent change: 3.16%Where is it least expensive to raise a child? 1. Birmingham, AL Total annual cost of raising a child in 2025: $19,082Total annual cost of raising a child in 2024: $20,754Percent change: -8.06% 2. Memphis, TN Total annual cost of raising a child in 2025: $19,264Total annual cost of raising a child in 2024: $18,677Percent change: 3.14% 3. Nashville-Davidson—Murfreesboro—Franklin, TN Total annual cost of raising a child in 2025: $20,787Total annual cost of raising a child in 2024: $20,412Percent change: 1.84% 4. Atlanta-Sandy Springs-Roswell, GA Total annual cost of raising a child in 2025: $20,821Total annual cost of raising a child in 2024: $22,095Percent change: -5.77% 5. San Antonio-New Braunfels, TX Total annual cost of raising a child in 2025: $20,945Total annual cost of raising a child in 2024: $21,014 Percent change: -0.33% LAPD chief speaks out about deployment of military forces to anti-ICE protests Australian reporter covering Los Angeles protests shot with rubber bullet by police officer Can Trump deploy National Guard without governor's approval?
Yahoo
an hour ago
- Yahoo
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
RAD101 in U.S. Phase 2 clinical trial to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin SYDNEY, June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RAD101 to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. RAD101 is the Company's novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including cerebral metastases. 'The FDA's Fast Track Designation for RAD101 highlights the seriousness of recurrent brain metastases as a condition and the unmet medical need for innovative products that can differentiate between tumor recurrence and radiation necrosis or pseudprogression,' said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. 'RAD101 represents a promising advancement in improving diagnostic precision for brain metastases, offering hope for more effective clinical decision-making in the over 300,000 patients diagnosed annually in the U.S. We are excited to advance our Phase 2 clinical trial and anticipate sharing topline results in the second half of 2025.' The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address an unmet medical need. A Sponsor that receives Fast Track designation may be eligible for more frequent meetings and communications with the FDA and rolling review of any application for marketing approval. A Sponsor's drug receiving Fast Track designation also may be eligible for Priority Review if relevant criteria are met. About the Phase 2 Clinical Trial of RAD101 The U.S. multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. The primary objective of the study is concordance between 18F-RAD101 positive lesions and those seen in conventional imaging (MRI with gadolinium) in participants with suspected recurrent brain metastases. Secondary endpoints are accuracy, sensitivity and specificity of RAD101 in identifying tumor recurrence versus radiation necrosis in previously stereotactic radiosurgery (SRS)-treated brain metastases. About RAD101 RAD101 is the Company's novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors, including cerebral metastasis. Targeting FASN activity may allow for the more accurate detection of cancer cells, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College of London's Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may potentially represent a non-invasive prediction of overall-survival, warranting larger studies. About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper. For more information: Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie FieldsPrecision AQ (Formerly Stern IR)E: Paul Hopper Executive Chairman P: +61 406 671 515 E: paulhopper@ MediaMatt WrightNWR CommunicationsP: +61 451 896 420E: matt@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
2 hours ago
- Forbes
Wired For Change: Endeavour Energy's Strategy For A Net-Zero Future
Between now and 2030, the energy network will change faster than it did in the last century. That's according to Guy Chalkley, CEO of Endeavour Energy. Chalkley was sharing his thoughts on navigating the energy transition at the recent SAP for Energy and Utilities 2025 conference in Rotterdam. 'Every success story is a tale of constant adaption, revision, and change,' he said, quoting Richard Branson, the British entrepreneur and founder of the Virgin Group. The topic of aviation was clearly on his mind—perhaps because he lives in a country where it takes five hours to fly from one side to the other. Endeavour Energy, the major network operator in New South Wales, Australia, delivers electricity to over 2.7 million people across the eastern coast of the country. 'We've typically added about 20,000 new customers each year,' Chalkley said. 'But what's really benefited Endeavour lately is a strong push—both from the federal and state governments—to move more people to Western Sydney.' Chalkley went on to explain that in ten years, 7 out of 10 new jobs and 7 out of 10 new residents will be based in Western Sydney. 'But it's not just about moving people—they're building the full infrastructure to support the move,' he said. 'A big part of this is the new Western Sydney International airport, which is acting as a major catalyst for all the development happening in the area.' Most airports are located in the middle of cities, so flights usually stop by 11 p.m. due to noise restrictions. Building a new airport in Western Sydney changes that. The new airport will operate 24/7 and be a major logistics hub. Amazon has already set up its central Australian distribution center there, along with many major supermarket distributors. The new airport will also open up access for international airlines, which currently struggle to get landing slots at Sydney's main airport. In addition, a brand-new city—Bradfield—is being developed around the airport and is expected to grow rapidly. The new airport is a transformative project for Australia's logistics and freight sectors, offering enhanced capacity, continuous operations, and integration with broader economic initiatives in the region. All of these developments come with a substantial demand for energy. Managing a complex energy system Endeavour Energy The energy ecosystem is complex. It includes transmission infrastructure to transport energy from generators such as wind or solar farms to supply stations. It includes electricity distributors such as Endeavour Energy to transport energy from the supply stations to the local substations, as well as retailers who handle billing and invoicing. It now also includes privately generated power and distributed energy resources (DER) to manage electricity that is generated and shared locally. With the rise of solar panels and home batteries, many households are now playing a direct role in creating and distributing energy. DER refers to the devices that can generate, store, and control energy to ensure its consumption at a particular time. The contribution of a single household to the network might seem insignificant, but the combined energy flow can have a significant impact on the network load. In this new scenario, energy is flowing two ways—from the customer to the network and vice versa, creating a challenge for traditional networks that were not designed for the two-way flow of power. Many adjustments are required to smooth the flows of fluctuating power and ensure power reliability. However, DER offers great benefits. When well managed, it allows more renewable power onto the network, which is often cost-effective. 'We are leveraging technology and data to plan the grid of the future where batteries, microgrids and solar integrate seamlessly with the traditional distribution network to power communities for a brighter future,' Chalkley explained. The company supplies an area over 25,000 square kilometers, with more than 430,000 power poles and streetlight columns, 202 major substations, and 32,600 distribution substations. They are all connected by nearly 60,600 kilometers of underground and overhead cables, more than the distance from Sydney to London and back. The network also integrates with renewable energy sources including 200,000 residential solar connections, industrial solar and embedded large-scale batteries. 'We're working with customers, stakeholders, and regulators to help deliver a clean energy future where smart meters, batteries, and solar enable customers to generate, store, and sell back electricity into the grid,' he said. For this reason, the company is deploying more than 80 community batteries throughout the network to alleviate some of the pressure on energy costs while increasing access to renewable energy. Chalkley highlighted the fact that such a vast network can't be reliable without being resilient to climate change. 'There's a growing dependence in society on electricity as we electrify everything,' he said. 'We have a detailed strategy for making our networks resilient against weather events like floods, bushfires, and increasing urban heat.' At Endeavour Energy, resilience is defined by the ability to anticipate, withstand, recover, and learn from major disruptive events. The resilience strategy includes: To achieve this level of resilience the company's strategy is fully aligned with the UN Sustainable Development Goals. 'From a distribution perspective, we're in a good place to actually effect change, as we're probably the link that allows other businesses to change,' Chalkley concluded. Because sustainability is not just an environmental issue, the company is engaging more with the community and customers. It is also investing heavily in innovation and in employee training to build the necessary skills and mindset for the future. Prepping for a net-zero future Endeavour Energy 'As a distribution company, our goal is to facilitate the transition to renewable energy to secure a more sustainable future,' he said.
